Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Usability of SCD411 Prefilled Syringe in AMD, RVO, DME, or DR
NCT07501052Phase 2Completed
- Sponsor
- Sam Chun Dang Pharm Co., Ltd.
- Start
- May 2026
- Primary completion
- May 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of SCD411 in neovascular age-related macular degeneration (NVAMD), retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), sponsored by Sam Chun Dang Pharm Co., Ltd.. Started May 2026; status: completed.
02
Drugs
SCD411
03
Conditions
neovascular age-related macular degeneration (NVAMD)retinal vein occlusion (RVO)diabetic macular edema (DME)diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT07501052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07501052.